Journal of Contemporary Brachytherapy

Abstract

5/2023 vol. 15
Review paper

The role of interventional radiotherapy (brachytherapy) in nasopharynx tumors: A systematic review

  1. U.O. Radioterapia Oncologica, A.O.U. Policlinico “G. Rodolico-San Marco” Catania, Catania, Italy,
  2. U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy
  3. Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia-U.O.C. Radiologia Diagnostica e Interventistica Generale, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  4. Multidisciplinary Research Center on Brain Tumors Diagnosis and Treatment, University of Catania, Italy
  5. Department Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia”, Università di Catania, Italy
  6. Università Cattolica del Sacro Cuore, Gemelli-INTERACTS, Rome, Italy
  7. Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Settore Scientifico Disciplinare, Università di Bologna, Bologna, Italy
  8. Division of Otolaryngology, Università di Sassari, Italy
  9. Università Cattolica del Sacro Cuore, Roma, Italy
J Contemp Brachytherapy 2023; 15, 5: 383–390
Online publish date: 2023/10/30
View full text

Purpose:

Nasopharyngeal cancers (NPC) are very aggressive, and the recurrence rate after radical therapy is high. This study aimed to evaluate the efficacy of brachytherapy (BT) also called interventional radiotherapy (IRT) in primary NPC in comparison with external beam radiotherapy (EBRT) alone.

Material and methods:

A systematic search was performed in Scopus, Cochrane, and PubMed databases. Clinical query based on PICO framework was as follows: In patients with NPC (P), is EBRT plus IRT (I) superior to EBRT alone (C) in terms of local control (LC) and toxicity (O)? Full articles evaluating the efficacy of IRT as a boost after EBRT in patients with NPC were considered.

Results:

Eight papers, including 1,320 patients fulfilled the inclusion criteria. The median 5-year LC for IRT group and no-IRT group was 98% (range, 95.8-100%) and 86% (range, 80.2-91%), respectively; the median 5-year overall survival (OS) for IRT group and no-IRT group was 93.3% (range, 89.2-97.5%) and 82.9% (range, 74.8-91.1%), respectively; the median 5-year DFS for IRT group and no-IRT group was 94.2% (range, 92.5-96%) and 83.9% (range, 73.3-94.6%), respectively; the median 5-year cancer-specific survival (CSS) for IRT group and no-IRT group was 96% (range, 94.5-97.5%) and 88.2% (range, 83.4-93.1%), respectively. G1-2 and G3-4 toxicities were similar in some articles, or significantly lower in patients treated with IRT in other papers.

Conclusions:

Data suggest that IRT may improve results of external beam radiotherapy in primary NPCs, especially when using new technologies.

Share
without publication fees